Ignite Creation Date:
2025-12-26 @ 2:43 PM
Ignite Modification Date:
2026-01-26 @ 11:15 AM
Study NCT ID:
NCT02555306
Status:
COMPLETED
Last Update Posted:
2020-01-14
First Post:
2015-09-13
Is NOT Gene Therapy:
True
Has Adverse Events:
True
Brief Title:
A Phase I/II Safety, Tolerability, Immunogenicity, and Bioactivity Study of DE-122 Injectable Solution for Refractory Exudative Age-related Macular Degeneration
Sponsor:
Santen Inc.
Organization:
Key Dates - Follows AllAPIJSON File Order
Start Date:
2015-09-16
Start Date Type:
ACTUAL
Primary Completion Date:
2017-08
Primary Completion Date Type:
ACTUAL
Completion Date:
2017-08
Completion Date Type:
ACTUAL
First Submit Date:
2015-09-13
First Submit QC Date:
None
Study First Post Date:
2015-09-21
Study First Post Date Type:
ESTIMATED
Results First Submit Date:
2019-10-11
Results First Submit QC Date:
None
Results First Post Date:
2020-01-14
Results First Post Date Type:
ACTUAL
Results First Post QC Date:
None
Results First Post QC Date Type:
None
Disp First Submit Date:
None
Disp First Submit QC Date:
None
Disp First Post Date:
None
Disp First Post Date Type:
None
Last Update Submit Date:
2020-01-10
Last Update Post Date:
2020-01-14
Last Update Post Date Type:
ACTUAL